Evaluating drug effects in the post-Vioxx world: there must be a better way. [electronic resource]
Producer: 20060607Description: 2173-6 p. digitalISSN:- 1524-4539
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Clinical Trials as Topic -- standards
- Cyclooxygenase 2 Inhibitors -- adverse effects
- Drug Approval -- legislation & jurisprudence
- Drug Costs
- Drug and Narcotic Control -- legislation & jurisprudence
- Duty to Warn -- legislation & jurisprudence
- Humans
- Information Dissemination
- Lactones -- adverse effects
- Myocardial Infarction -- chemically induced
- Probability
- Product Surveillance, Postmarketing -- standards
- Research Design
- Risk Assessment
- Stroke -- chemically induced
- Sulfones -- adverse effects
- Treatment Outcome
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Comment; Editorial
There are no comments on this title.
Log in to your account to post a comment.